SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Drugs that provide the splice of life: Motor neurons relay signals from the nervous system to muscle fibers. In patients with spinal muscular atrophy, a protein required for the survival of these neurons is deficient or missing altogether, so the neurons gradually die and the patients' muscles waste away. The disease is currently untreatable. Naryshkin et al. discovered small-molecule drugs that cause cells to produce the missing protein by altering how a specific mRNA is put together, or “spliced” (see the Perspective by Vigevani and Valcárcel). When the researchers used the drugs to treat diseased mice, the mice showed marked improvement in muscle mass, motor function, and survival. Science , this issue p. 688 ; see also p. 624
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These screens, which are typically conducted in genetically engineered cell lines that harbour the target of interest, led to the discovery of the splice modulators risdiplam106 and branaplam107 for the treatment of spinal muscular atrophy”
From Human disease models in drug development (2023) · cites this paper as [106]
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
GMAP: A genomic mapping and alignment program for mRNA and EST sequences
Wu, T. D., & Watanabe, C. K. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti310 · Cited by 2,354
Fast and SNP-tolerant detection of complex variants and splicing in short reads
Wu, T. D., & Nacu, S. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq057 · Cited by 1,894
Lorson, C. L., Hahnen, E., Androphy, E. J., & Wirth, B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6307 · Cited by 1,532
Feldkötter, M., Schwarzer, V., Wirth, R., Wienker, T. F., & Wirth, B. (2002) · The American Journal of Human Genetics · doi:10.1086/338627 · Cited by 1,004
Consensus Statement for Standard of Care in Spinal Muscular Atrophy
Wang, C. H., Finkel, R. S., Bertini, E. S., Schroth, M., Simonds, A., Wong, B., Aloysius, A., Morrison, L., Main, M., Crawford, T. O., et al. (2007) · Journal of Child Neurology · doi:10.1177/0883073807305788 · Cited by 961
Hua, Y., Sahashi, K., Rigo, F., Hung, G., Horev, G., Bennett, C. F., & Krainer, A. R. (2011) · Nature · doi:10.1038/nature10485 · Cited by 741
Cited by
Items 401–500 of 533
An, J., Wang, H., Wei, M., Yu, X., Liao, Y., Tan, X., Hu, C., Li, S., Luo, Y., Gui, Y., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.139119 · Cited by 3
Zhang, P., Taghavi, A., Abe, M., Aikawa, H., Akahori, Y., Chen, J. L., Tong, Y., Baisden, J. T., Cameron, M. D., Childs‐Disney, J. L., et al. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00260 · Cited by 3
Induced pluripotent stem cell technology: venturing into the second decade
Shi, Y., Inoue, H., Takahashi, J. B., & Yamanaka, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818422-6.00095-2 · Cited by 5
Polypharmacology in Drug Design and Discovery—Basis for Rational Design of Multitarget Drugs
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_12 · Cited by 3
Splice-modifying drug mechanisms
Herrero-Vicente, J., Black, D. L., & Valcárcel, J. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01678-2 · Cited by 3
The Paracrine Neural Stem Cell Niche: New Actors in the Play
Gómez‐Gaviro, M. V., & Desco, M. (2018) · Current Stem Cell Reports · doi:10.1007/s40778-018-0112-1 · Cited by 4
Targeting RNA with Small Molecules
Zhang, P., Bush, J. A., Childs‐Disney, J. L., & Disney, M. D. (2023) · Springer eBooks · doi:10.1007/978-981-19-9776-1_96 · Cited by 3
Advances in Spinal Muscular Atrophy Research
Melki, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803685-3.06001-8 · Cited by 3
Chen, D., Philippidou, P., Brenha, B. D. F., Schaffer, A. E., & Miranda, H. C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.11.575304 · Cited by 3
Presymptomatic Treatment of a Genetic Disease with a Small-Molecule Drug
Sumner, C. J. (2025) · New England Journal of Medicine · doi:10.1056/nejme2507195 · Cited by 3
Phenotypic approaches for CNS drugs
Sharma, R., Oyagawa, C. R. M., Abbasi, H., Dragunow, M., & Conole, D. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.09.003 · Cited by 4
Kuang, Z., Kosmyna, B., Li, X., Tang, Z., Shi, S., Lambert, K. A., Zhang, W., Giovinazzo, J. A., Effenberger, K. A., Sierra, J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-74765-8 · Cited by 3
The “five-star matrix” for patient-centric drug discovery and development in neuroscience
Pähler, A., O’Connor, E. C., Binch, H., Dudal, S., Gobbi, L. B., Lübbers, T., Olivares‐Morales, A., Sarmiento, R. M. R., Grether, U., Ståhl, M., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.08.004 · Cited by 3
Exploring Secondary Structure Predictions for RNA-Targeted Drug Discovery: Power and Challenges
Zhang, Z., Dolcetti, G., Tyrchan, C., Maria, L. D., Bussi, G., & Czechtizky, W. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c00108 · Cited by 2
Tang, Z., Hegde, S., Zhao, J., Zhu, S., Johnson, K. A., Lorson, C. L., & Wang, J. (2022) · ChemBioChem · doi:10.1002/cbic.202200012 · Cited by 2
Campagne, S., de Vries, T., & Allain, F. H. ‐. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2521-7_15 · Cited by 2
Risdiplam for the treatment of spinal muscular atrophy
Владимирович, В. Д. (2024) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202412402145 · Cited by 2
Yu, L., Sun, L., Yue, X., Wang, Y., & Chen, C. (2025) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2025.105081 · Cited by 6
Elsheikh, B., Kolb, S. J., & Kissel, J. T. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813866-3.00022-9 · Cited by 2
Current and emerging treatment options for spinal muscular atrophy
Farooq, F., & MacKenzie, A. (2015) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s48420 · Cited by 2
Big Genome Data Classification with Random Forests Using VariantSpark
Devi, A. S., & Maragatham, G. (2018) · Lecture notes on data engineering and communications technologies · doi:10.1007/978-981-10-8681-6_55 · Cited by 3
Jorgensen, S., Lau, M., & Arnold, W. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-62539-5.00040-0 · Cited by 5
Emergencies in Motor Neuron Diseases
Servais, L., & Damme, P. V. (2022) · Springer eBooks · doi:10.1007/978-3-030-91932-0_6 · Cited by 2
Development and Optimization of the Manufacturing Process for RNA-Splicing Modifier Risdiplam RG7916
Moessner, C., Hoffmann-Emery, F., Adam, J., Fantasia, S., Fishlock, D., Meier, R., Wuitschik, G., & Ratni, H. (2022) · ACS symposium series · doi:10.1021/bk-2022-1423.ch008 · Cited by 4
Self-citationNovikova, E. S. (2023) · Annals of Clinical and Experimental Neurology · doi:10.54101/acen.2023.3.11 · Cited by 2
Spinal Muscular Atrophy: Huge Steps.
Howell, K., Gibbs, R. M., & Rubin, L. L. (2019) · PubMed Central · Cited by 2
Self-citationLi, J. J. (2022) · Wiley eBooks · doi:10.1002/9781119847281.ch15 · Cited by 2
Malard, F., Wolter, A. C., Marquevielle, J., Morvan, E., Allain, F. H. ‐., & Campagne, S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.31.535100 · Cited by 2
“There are two classes of small molecule splicing modifiers that have been described: the SMN2 and the HTT splicing modifiers, both of which act on A-1 bulged 5'-splice sites (16, 18).”
BackgroundA Sequential Binding Mechanism for 5’ Splice Site Recognition and Modulation for the Human U1 snRNPPreprint
White, D. S., Dunyak, B. M., Vaillancourt, F. H., & Hoskins, A. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.18.590139 · Cited by 2
Chen, D., Philippidou, P., Brenha, B. D. F., Schaffer, A. E., & Miranda, H. C. (2024) · eLife · doi:10.7554/elife.95388 · Cited by 2
Chen, D., Philippidou, P., Brenha, B. D. F., Schaffer, A. E., & Miranda, H. C. (2024) · eLife · doi:10.7554/elife.95388.1 · Cited by 2
Mechanistic Studies of Small Molecule Ligands Selective to RNA Single G BulgesPreprint
Hegde, S., Akhter, S., Tang, Z., Qi, C., Yu, C., Lewicka, A., Liu, Y., Koirala, K., Reibarkh, M., Battaile, K. P., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.14.618236 · Cited by 2
Cell Culture Models of Spinal Muscular Atrophy
Ng, S., & Rubin, L. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803685-3.00013-6 · Cited by 1
Self-citationRecent Advance in Disease Modifying Therapies for Spinal Muscular Atrophy
Tsai, L., Ting, C.-H., Liu, Y., Hsiao, C.-T., Weng, W., & Society for Neurological Rare Disorders-Taiwan (2024) · Acta Neurologica Taiwanica · doi:10.4103/ant.33-3_review · Cited by 1
Drug discovery technologies–Current and future trends
Noe, M. C., Steppan, C. M., & Weston, A. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00019-4 · Cited by 1
Risdiplam: A Small Molecule mRNA Splice Modifier Approved to Treat SMA Disease
Müller, L., Jacobsen, B., & Nürnberg, A. (2025) · Toxicologic Pathology · doi:10.1177/01926233251392863 · Cited by 2
Advantages and Challenges of G-Quadruplexes in Regulating Alternative Splicing
Huang, H., & Zhou, X. (2026) · JACS Au · doi:10.1021/jacsau.6c00168 · Cited by 2
Meeting Report: New Directions in Biology and Disease of Skeletal Muscle 2014
Wyatt, E. J., Sweeney, H. L., & McNally, E. M. (2014) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-149003 · Cited by 1
Beefing up the right splice variant to treat spinal muscular atrophy
Cully, M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4445 · Cited by 1
Miller, B. L. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1839 · Cited by 1
Can Holo NMR Chemical Shifts be Directly Used to Resolve RNA–Ligand Poses?
Frank, A. T. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00593 · Cited by 1
Ladomery, M., & Oltean, S. (2016) · Springer eBooks · doi:10.1007/978-3-319-38882-3_3 · Cited by 1
Miranda, H. C., & Spada, A. R. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-30582-0_11 · Cited by 1
Hoffman, E. P., Bönnemann, C. G., Boutin, M., Brais, B., Buccella, F., Burghes, A. H. M., Coffey, C. S., Dasgupta, N., Dawkins, H. J. S., Luca, A. D., et al. (2017) · Neuromuscular Disorders · doi:10.1016/j.nmd.2017.02.013 · Cited by 1
Antisense oligonucleotide drugs for neurological and neuromuscular disease
Lane, R. M., & Bennett, C. F. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813955-4.00017-9 · Cited by 1
Induced pluripotent stem cells for modeling of spinal muscular atrophy
Welby, E., & Ebert, A. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85764-2.00010-7 · Cited by 1
Regulation of Survival Motor Neuron Gene Expression by Calcium Signaling
Choi, K., Yang, A., Baek, J., Jeong, H., Kang, Y., Baek, W., Kim, J., Kang, M., Choi, M., Ham, Y., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910234 · Cited by 1
Tuszynski, M. H. (2016) · Springer eBooks · doi:10.1007/978-1-4899-7654-3_1 · Cited by 1
Deconinck, N., & Devos, E. (2022) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2022.2152671 · Cited by 1
Chemical Tools to Target Noncoding RNAs
Bonnet, M., & Duca, M. (2023) · Springer eBooks · doi:10.1007/978-981-19-9776-1_36 · Cited by 1
Ratni, H., Ebeling, M., Scalco, R., Mueller, L. A., & Stephan, A. H. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781788018982-00830 · Cited by 1
Self-citationPattern of pareses in 5q-spinal muscular atrophy
Uzelac, Ž., Schwäble, B., Dorst, J., Rosenbohm, A., Wollinsky, K. H., Wurster, C. D., Steinbreier, J. S., & Ludolph, A. C. (2024) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864241263420 · Cited by 2
Drug Repurposing in CNS Disorders
Hussain, N., Singh, S., & Alexander, A. (2024) · Springer eBooks · doi:10.1007/978-981-97-5016-0_7 · Cited by 1
Therapeutic Strategies in Neurodegenerative Diseases
Eid, A. M., Faridar, A., & Appel, S. H. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_39 · Cited by 2
Yaszay, B., & Scannell, B. P. (2015) · Springer eBooks · doi:10.1007/978-3-662-48284-1_13 · Cited by 1
Long, P., Shi, Y., Sun, F., Wei, Y., Wu, B., Li, Q., Jie, Q., & Ma, Y.-L. (2022) · Journal of clinical laboratory analysis (Print) · doi:10.1002/jcla.24464
Molecular pathogenesis of a novel Met394Thr variant causing hemophilia B
Lu, L., Wang, L., Shen, W., Fang, S., Zhao, L., Hu, X., Yang, L., & Wang, G. (2023) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.2147
“For splicing variants, one study reported that selective SMN2 gene splicing modifiers have therapeutic potential for spinal muscular atrophy (Naryshkin et al., 2014).”
BackgroundTranslatability: what does it mean in drug discovery?
Tudor, M., Hermes, J. D., & Li, J. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.03.010 · Cited by 1
AI-Generated Virtual Libraries Could Help Uncover RNA-Specific Regions of Chemical SpacePreprint
Xu, Z., & Frank, A. T. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.05.479230 · Cited by 1
Kordala, A. J., Ahlskog, N., Hanifi, M., Bhomra, A., Stoodley, J., Lim, W. F., Hammond, S. M., Wood, M. J. A., & Rinaldi, C. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.18.512489 · Cited by 1
Predicting Small Molecule Ligand – RNA Binding Pocket Binding Modes Using MetadynamicsPreprint
Bai, Z., & Chen, A. A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.04.560960 · Cited by 1
Wang, J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.08.617329 · Cited by 1
“…(e.g., pseudoknots (5, 6), G-quadruplexes (7), and riboswitches (8)), dynamic structures in conformational equilibrium (9, 10), or transiently formed structures (11–14), many small molecules target short, stable RNA secondary structures, such as stem-loops, internal loops, and bulges (15–19).”
BackgroundChao, K.-H., Mao, A., Liu, A., Salzberg, S. L., & Pertea, M. (2025) · eLife · doi:10.7554/elife.107454.1 · Cited by 2
Bohl, D. (2016) · Biologie Aujourd hui · doi:10.1051/jbio/2016004
“At the meantime, a newly discovered compound that shifted the balance of SMN2 splicing toward the production of full-length SMN2 messenger RNA with high selectivity was reported to improve motor function and longevity in SMA 7 mice (Naryshkin et al, 2014).”
Post-Transcriptional Gene Regulation by MicroRNA and RNA-Binding Protein
Chiba, T., Ito, Y., & Asahara, H. (2016) · doi:10.11648/j.bs.20160203.11
Pluripotent Stem Cells for Modeling Motor Neuron Diseases
Bohl, D. (2016) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-319-33270-3_5
Balachandran, A. (2015) · TSpace (University of Toronto)
Motor Neuron-Related Disorders
Li, L., Liu, Z., Chen, W., Wang, H., Li, H., & Chen, S. (2017) · Springer eBooks · doi:10.1007/978-981-10-4196-9_3
Cellular Therapy for Spinal Muscular Atrophy
Faravelli, I., & Corti, S. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802257-3.00011-0
Powis, R. A. (2016) · Edinburgh Research Archive (University of Edinburgh)
Kanda, S. (2018) · Library, Museums and Press - UDSpace (University of Delaware) · doi:10.58088/2ppe-ex16
Serrano‐Pertierra, E. (2018) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Fischbeck, K. H. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803685-3.06003-1
Using In Vitro and In-cell SHAPE to Investigate Small Molecule Induced Pre-mRNA Structural Changes
Wang, J., Hammond, J. A., & Johnson, K. A. (2019) · Journal of Visualized Experiments · doi:10.3791/59021
Efficacy of Novel Antisense Oligonucleotides for the Treatment of Spinal Muscular Atrophy
Touznik, A. (2016) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3hh6cm50
Optimisation of lentiviral vectors for gene therapy of spinal muscular atrophy
Nafchi, N. A. M. (2017)
Swalley, S. E., & Cheung, A. K. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160721-00140
Induced Pluripotent Stem Cells (iPSCs) Technology: Potential Targets for Depression
Colpo, G. D., & Teixeira, A. L. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6044-0_24
Inference of Computational Models of Alternative Polyadenylation and Splicing
Leung, M. K. K. (2018) · TSpace (University of Toronto)
Gentherapie bei spinaler Muskelatrophie -ein Update
Brakemeier, S., Kleinschnitz, C., & Hagenacker, T. (2021) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-021-1916-6
Ratni, H. (2021) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2021.614
Self-citationXia, C., Dai, R., Yu, J., Zhang, C., Wong, M., & Liu, C. (2021) · Research Square · doi:10.21203/rs.3.rs-1184033/v1
Numao, S., Etienne, G., Malojcic, G., Schmidt, E. K., & Dumelin, C. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00078-5
Fletcher, S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727480507.793560197
Kanda, S., Moulton, E., & Butchbach, M. E. R. (2022) · Molecular Pharmacology · doi:10.1124/molpharm.122.000529
Obulesu, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-95762-5.00007-2
The cancer-associated RBM39 bridges the pre-mRNA, U1 and U2 snRNPs to regulate alternative splicingPreprint
Campagne, S., Jutzi, D., Malard, F., Matoga, M., Romane, K., Feldmüller, M., Colombo, M., Ruepp, M., & Allain, F. H. ‐. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.30.505862
Improving three-dimensional human pluripotent cell culture efficiency via surface molecule coating
Li, Q., Pan, Y., Han, L., Yang, Y., Wu, X., & Lei, Y. (2022) · Frontiers in Chemical Engineering · doi:10.3389/fceng.2022.1031395 · Cited by 1
“They have been applied for screening new drugs (Höing et al., 2012; Naryshkin et al., 2014; Bright et al., 2015; Kumari et al., 2015; McNeish et al., 2015), testing drug toxicity (Matsa et al.”
MethodByun, W. G. (2022) · Springer theses · doi:10.1007/978-981-19-7814-2_1
Induced Pluripotent Stem Cells: Progress toward Clinical Translation from Bench to Bedside
Fakoya, A. O. J., Omole, A. E., Satyadev, N., & Haider, K. H. (2022) · Springer eBooks · doi:10.1007/978-981-19-2655-6_40
Gentherapien bei den Motoneuronerkrankungen ALS und SMA
Günther, R. (2023) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2002-5215
Chemical Tools to Target Noncoding RNAs
Bonnet, M., & Duca, M. (2023) · Springer eBooks · doi:10.1007/978-981-16-1313-5_36-1 · Cited by 1
Targeting RNA with Small Molecules
Zhang, P., Bush, J. A., Childs‐Disney, J. L., & Disney, M. D. (2023) · Springer eBooks · doi:10.1007/978-981-16-1313-5_96-1
Barraza, S. J., & Woll, M. G. (2024) · Methods and principles in medicinal chemistry · doi:10.1002/9783527840458.ch7
Self-citationRNA Modifying Proteins: Emerging Targets for Drug Discovery
Boriack‐Sjodin, P. A., & Silver, S. J. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674916-00500
Drug Discovery for Chromatin Readers, Writers, Erasers, Remodelers and Epitranscriptomic Targets
(2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674916-part3
Antisense oligonucleotide drugs for neurological and neuromuscular diseases
Lane, R. M., & Bennett, C. F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19041-4.00039-x
Off‐Target Screening Strategies
Roberts, S., & Lightfoot, H. L. (2024) · Wiley eBooks · doi:10.1002/9781394182862.ch4
Metadata
- Authors
- Naryshkin, N. A., Weetall, M., Dakka, A., Narasimhan, J., Zhao, X., Feng, Z., Ling, K. K. Y., Karp, G. M., Qi, H., Woll, M. G., Chen, G., Zhang, N., Gabbeta, V., Vazirani, P., Bhattacharyya, A., Furia, B., Risher, N., Sheedy, J., Kong, R., Ma, J., Turpoff, A., Lee, C.-S., Zhang, X., Moon, Y.-C., Trifillis, P., Welch, E. M., Colacino, J. M., Babiak, J., Almstead, N. G., Peltz, S. W., Eng, L. A., Chen, K. S., Mull, J. L., Lynes, M. S., Rubin, L. L., Fontoura, P., Santarelli, L., Haehnke, D., McCarthy, K. D., Schmucki, R., Ebeling, M., Sivaramakrishnan, M., Ko, C.-P., Paushkin, S. V., Ratni, H., Gerlach, I., Ghosh, A., & Metzger, F.
- Affiliations
- PTC Therapeutics (United States) (US)
- University of Southern California (US)
- Spinal Muscular Atrophy Foundation (US)
- Harvard University (US)
- F. Hoffmann-La Roche AG (CH)
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Grenzacherstrasse 124, 4070 Basel, Switzerland.
- Corresponding author
- Peltz, Stuart W.
- Metzger, Friedrich
- ORCID
- Naryshkin, Nikolai A.
- Weetall, Marla
- Narasimhan, Jana
- Zhao, Xin
- Ling, Karen K. Y.
- Chen, Guangming
- Zhang, Nanjing
- Sheedy, Josephine
- Kong, Ronald
- Ma, Jiyuan
- Moon, Young-Choon
- Welch, Ellen M.
- Colacino, Joseph M.
- Peltz, Stuart W.
- Chen, Karen S.
- Rubin, Lee L.
- Fontoura, Paulo
- Ebeling, Martin
- Ko, Chien-Ping
- Paushkin, Sergey V.
- Ratni, Hasane
- Metzger, Friedrich
- Venue
- Science
- Published
- 2014-08-08
- Volume
- 345
- Issue
- 6197
- Pages
- 688-693
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1992985034
- Cited by
- 524
- References
- 56
- Citations by year
- 2026: 19 · 2025: 40 · 2024: 47 · 2023: 33 · 2022: 50 · 2021: 54 · 2020: 34 · 2019: 47 · 2018: 50 · 2017: 44 · 2016: 59 · 2015: 35 · 2014: 12
- FWCI
- 25.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Keywords
- spinal muscular atrophy, SMN2, SMN1, alternative splicing, small molecules, SMN protein, motor function, lifespan extension, neuromuscular degeneration, compound screening
- MeSH terms
- Administration, Oral, Animals, Cells, Cultured, Coumarins, Disease Models, Animal, Drug Evaluation, Preclinical, Humans, Longevity, Muscular Atrophy, Spinal, Pyrimidinones, RNA, Messenger, Sequence Deletion, Alternative Splicing, Isocoumarins, Mice, Small Molecule Libraries, Survival of Motor Neuron 2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.